GMAB vs ARXS Comparison

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Arxis Inc designs and manufactures proprietary electronic and mechanical components used in applications that require performance in extreme environments. The company operates in two reportable segments: i) Electronic Components: It provides specialized, engineered electronic components and interconnect solutions, including connectors, cable assemblies, microelectronic packaging, RF and microwave products, power products, sensors, capacitors and resistors. and ii) Mechanical Components: It provides precision and self-lubricating bearings, seals, springs, gaskets and ducting, and radar absorbing materials. The majority of the company's revenue is derived from the Mechanical Components segment. Geographically, it generates the maximum revenue from the United States.